IQVIA Holdings Inc. (NYSE:IQV) Shares Bought by Whittier Trust Co. of Nevada Inc.

Whittier Trust Co. of Nevada Inc. grew its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 2.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 49,182 shares of the medical research company’s stock after purchasing an additional 1,026 shares during the quarter. Whittier Trust Co. of Nevada Inc.’s holdings in IQVIA were worth $11,654,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of IQV. First Foundation Advisors boosted its stake in shares of IQVIA by 3.8% in the second quarter. First Foundation Advisors now owns 1,161 shares of the medical research company’s stock valued at $245,000 after purchasing an additional 43 shares during the period. Team Hewins LLC grew its position in shares of IQVIA by 5.0% during the first quarter. Team Hewins LLC now owns 973 shares of the medical research company’s stock worth $246,000 after buying an additional 46 shares in the last quarter. Invera Wealth Advisors LLC raised its holdings in IQVIA by 0.3% in the second quarter. Invera Wealth Advisors LLC now owns 14,506 shares of the medical research company’s stock valued at $3,183,000 after acquiring an additional 46 shares in the last quarter. Covestor Ltd boosted its stake in IQVIA by 45.3% during the 1st quarter. Covestor Ltd now owns 154 shares of the medical research company’s stock valued at $39,000 after acquiring an additional 48 shares during the last quarter. Finally, Oregon Public Employees Retirement Fund grew its holdings in IQVIA by 0.3% during the 2nd quarter. Oregon Public Employees Retirement Fund now owns 15,668 shares of the medical research company’s stock worth $3,313,000 after acquiring an additional 48 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at IQVIA

In related news, insider Eric Sherbet sold 1,300 shares of IQVIA stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total value of $320,229.00. Following the transaction, the insider now directly owns 19,536 shares in the company, valued at $4,812,302.88. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 1.60% of the stock is owned by corporate insiders.

IQVIA Price Performance

IQV stock traded down $5.66 during trading hours on Monday, hitting $231.03. 457,602 shares of the stock traded hands, compared to its average volume of 1,063,540. The company has a current ratio of 0.85, a quick ratio of 0.85 and a debt-to-equity ratio of 1.80. The stock has a 50-day simple moving average of $239.08 and a 200 day simple moving average of $231.08. IQVIA Holdings Inc. has a one year low of $167.42 and a one year high of $261.73. The company has a market cap of $42.12 billion, a P/E ratio of 30.74, a P/E/G ratio of 2.22 and a beta of 1.49.

IQVIA (NYSE:IQV) last released its earnings results on Monday, July 22nd. The medical research company reported $2.64 EPS for the quarter, topping analysts’ consensus estimates of $2.57 by $0.07. The business had revenue of $3.81 billion for the quarter, compared to the consensus estimate of $3.79 billion. IQVIA had a net margin of 9.39% and a return on equity of 28.59%. The business’s revenue for the quarter was up 2.3% on a year-over-year basis. During the same period in the previous year, the firm earned $2.22 EPS. Equities analysts forecast that IQVIA Holdings Inc. will post 10.25 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently commented on IQV. Barclays decreased their price target on IQVIA from $275.00 to $260.00 and set an “overweight” rating for the company in a research note on Tuesday, October 15th. Evercore ISI lowered their price target on IQVIA from $270.00 to $265.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th. Robert W. Baird upped their price target on IQVIA from $251.00 to $256.00 and gave the company a “neutral” rating in a research report on Friday, September 20th. JPMorgan Chase & Co. lifted their price objective on shares of IQVIA from $260.00 to $288.00 and gave the stock an “overweight” rating in a report on Monday, August 5th. Finally, Truist Financial dropped their target price on shares of IQVIA from $300.00 to $286.00 and set a “buy” rating on the stock in a report on Monday, October 14th. Four research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, IQVIA currently has an average rating of “Moderate Buy” and an average price target of $267.87.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.